Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Oct;48(4):595–598. doi: 10.1038/bjc.1983.233

Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer.

A L Harris, M D Mitchell, I E Smith, T J Powles
PMCID: PMC2011503  PMID: 6688732

Full text

PDF
595

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alam M., Jogee M., MacGregor W. G., Dowdell J. W., Elder M. G., Myatt L. Peripheral plasma immunoreactive 6-oxo-prostaglandin F1 alpha and gynaecological tumours. Br J Cancer. 1982 Mar;45(3):384–389. doi: 10.1038/bjc.1982.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barcikowski B., Carlson J. C., Wilson L., McCracken J. A. The effect of endogenous and exogenous estradiol-17beta on the release of prostaglandin F2alpha from the ovine uterus. Endocrinology. 1974 Nov;95(5):1340–1349. doi: 10.1210/endo-95-5-1340. [DOI] [PubMed] [Google Scholar]
  3. Bennett A., Berstock D. A., Harris M., Raja B., Rowe D. J., Stamford I. F., Wright J. E. Prostaglandins and their relationships to malignant and benign human breast tumors. Adv Prostaglandin Thromboxane Res. 1980;6:595–600. [PubMed] [Google Scholar]
  4. Bennett A., Edwards D., Ali N. N., Auger D., Harris M. Prostacyclin potently resorbs bone in vitro. Adv Prostaglandin Thromboxane Res. 1980;6:547–548. [PubMed] [Google Scholar]
  5. Bennett A., McDonald A. M., Simpson J. S., Stamford I. F. Breast cancer, prostaglandins, and bone metastases. Lancet. 1975 May 31;1(7918):1218–1220. doi: 10.1016/s0140-6736(75)92197-2. [DOI] [PubMed] [Google Scholar]
  6. Blackwell G. J., Carnuccio R., Di Rosa M., Flower R. J., Parente L., Persico P. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature. 1980 Sep 11;287(5778):147–149. doi: 10.1038/287147a0. [DOI] [PubMed] [Google Scholar]
  7. Caldwell B. V., Tillson S. A., Brock W. A., Speroff L. The effects of exogenous progesterone and estradiol on prostaglandin F levels in ovariectomized ewes. Prostaglandins. 1972 Mar;1(3):217–228. doi: 10.1016/0090-6980(72)90006-8. [DOI] [PubMed] [Google Scholar]
  8. Dexter R. N., Fishman L. M., Ney R. L., Liddle G. W. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action. J Clin Endocrinol Metab. 1967 Apr;27(4):473–480. doi: 10.1210/jcem-27-4-473. [DOI] [PubMed] [Google Scholar]
  9. Dowsett M., Easty G. C., Powles T. J., Easty D. M., Neville A. M. Human breast tumour-induced osteolysis and prostaglandins. Prostaglandins. 1976 Mar;11(3):447–460. doi: 10.1016/0090-6980(76)90078-2. [DOI] [PubMed] [Google Scholar]
  10. Faglia G., Gattinoni L., Travaglini P., Neri V., Acerbi L., Ambrosi B. Evidence suggesting 11 beta-hydroxylase inhibition during aminoglutethimide administration. Metabolism. 1971 Mar;20(3):266–272. doi: 10.1016/0026-0495(71)90109-0. [DOI] [PubMed] [Google Scholar]
  11. Fenwick L., Jones R. L., Naylor B., Poyser N. L., Wilson N. H. Production of prostaglandins by the pseudopregnant rat uterus, in vitro, and the effect of tamoxifen with the identification of 6-keto-prostaglandin F1alpha as a major product. Br J Pharmacol. 1977 Jan;59(1):191–199. doi: 10.1111/j.1476-5381.1977.tb06993.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fiedler L., Zahradnik H. P., Schlegel G. Perioperative behavior of prostaglandin E2 and 13,14-dihydro-15-keto-PGF2 alpha in serum of bronchial carcinoma patients. Adv Prostaglandin Thromboxane Res. 1980;6:585–586. [PubMed] [Google Scholar]
  13. Greaves M., Ibbotson K. J., Atkins D., Martin T. J. Prostaglandins as mediators of bone resorption in renal and breast tumours. Clin Sci (Lond) 1980 Mar;58(3):201–210. doi: 10.1042/cs0580201. [DOI] [PubMed] [Google Scholar]
  14. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. L. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer. 1983 May;47(5):621–627. doi: 10.1038/bjc.1983.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hirata F., Schiffmann E., Venkatasubramanian K., Salomon D., Axelrod J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci U S A. 1980 May;77(5):2533–2536. doi: 10.1073/pnas.77.5.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Maclouf J., Sors H., Rigaud M. Recent aspects of prostaglandin biosynthesis: a review. Biomedicine. 1977 Dec;26(6):362–375. [PubMed] [Google Scholar]
  17. Powles T. J., Dady P. J., Williams J., Easty G. C., Coombes R. C. Use of inhibitors of prostaglandin synthesis in patients with breast cancer. Adv Prostaglandin Thromboxane Res. 1980;6:511–516. [PubMed] [Google Scholar]
  18. Powles T. J., Dowsett M., Easty G. C., Easty D. M., Neville A. M. Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet. 1976 Mar 20;1(7960):608–610. doi: 10.1016/s0140-6736(76)90416-5. [DOI] [PubMed] [Google Scholar]
  19. Raisz L. G., Dietrich J. W., Simmons H. A., Seyberth H. W., Hubbard W., Oates J. A. Effect of prostaglaidin endoperoxides and metabolites on bone resorption in vitro. Nature. 1977 Jun 9;267(5611):532–534. doi: 10.1038/267532a0. [DOI] [PubMed] [Google Scholar]
  20. Ritchie G. A. The direct inhibition of prostaglandin synthetase of human breast cancer tumor tissue by tamoxifen. Recent Results Cancer Res. 1980;71:96–101. doi: 10.1007/978-3-642-81406-8_13. [DOI] [PubMed] [Google Scholar]
  21. Robinson J. S., Challis J. R., Furr B. J., Louis T. M., Thorburn G. D. Is the sheep corpus luteum subject to tonic inhibition during the luteal phase of the estrous cycle? Eur J Obstet Gynecol Reprod Biol. 1976;6(4):191–199. doi: 10.1016/0028-2243(76)90027-7. [DOI] [PubMed] [Google Scholar]
  22. Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980 May;64(5):1061–1070. [PubMed] [Google Scholar]
  23. Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin production and metabolism in human breast cancer. Adv Prostaglandin Thromboxane Res. 1980;6:575–580. [PubMed] [Google Scholar]
  24. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978 Dec;47(6):1257–1265. doi: 10.1210/jcem-47-6-1257. [DOI] [PubMed] [Google Scholar]
  25. Smith I. E., Harris A. L., Morgan M., Ford H. T., Gazet J. C., Harmer C. L., White H., Parsons C. A., Villardo A., Walsh G. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed) 1981 Nov 28;283(6304):1432–1434. doi: 10.1136/bmj.283.6304.1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stamford I. F., MacIntyre J., Bennett A. Human breast carcinomas release prostaglandin-like material into the blood. Adv Prostaglandin Thromboxane Res. 1980;6:571–573. [PubMed] [Google Scholar]
  27. Strickland D. M., Brennecke S. P., Mitchell M. D. Measurement of 13,14-dihydro-15-keto-prostaglandin F2 alpha and 6-keto-prostaglandin F1 alpha in plasma by radioimmunoassay without prior extraction or chromatography. Prostaglandins Leukot Med. 1982 Nov;9(5):491–493. doi: 10.1016/0262-1746(82)90029-4. [DOI] [PubMed] [Google Scholar]
  28. Wilkinson P., Ribeiro G., Adam H., Patterson J. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer. Cancer Chemother Pharmacol. 1980;5(2):109–111. doi: 10.1007/BF00435413. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES